Article
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
The European respiratory journal - 1 Dec 2023
Daines Cori L, Tullis Elizabeth, Costa Stefano, Linnemann Rachel W, Mall Marcus A, McKone Edward F, Polineni Deepika, Quon Bradley S, Ringshausen Felix C, Rowe Steven M, Selvadurai Hiran, Taylor-Cousar Jennifer L, Withers Nicholas J, Ahluwalia Neil, Moskowitz Samuel M, Prieto-Centurion Valentin, Tan Yaoyuan Vincent, Tian Simon, Weinstock Tanya, Xuan Fengjuan, Zhang Yaohua, Ramsey Bonnie, Griese Matthias
Abstract excerpt
BACKGROUND: In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) ≥12 years of age who have at least one F508del allele. The aim of this study is to assess long-term safety and efficacy of ELX/TEZ/IVA in these patients. METHODS: In this phase 3, open-label, single-arm extension study,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.